Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MINIZIDE vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Prazosin is a selective alpha-1 adrenergic antagonist that inhibits vascular smooth muscle contraction, reducing peripheral vascular resistance and blood pressure. Polythiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing sodium and water excretion, and reducing intravascular volume.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension
Hypertension
1-2 capsules orally twice daily; each capsule contains prazosin 0.5 mg and polythiazide 0.5 mg. Titrate based on blood pressure response.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
2-3 hours (prazosin component); prolonged in heart failure or renal impairment
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Prazosin is extensively metabolized in the liver via O-demethylation and conjugation, primarily by CYP3A4. Polythiazide is not extensively metabolized; it is excreted unchanged in the urine.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal: 90% (unchanged drug and metabolites); biliary/fecal: <10%
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
97% (prazosin bound to alpha-1 acid glycoprotein and albumin)
~90%, primarily to albumin
0.6 L/kg (prazosin); reflects extensive tissue distribution
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 50-70% (prazosin); first-pass metabolism reduces systemic availability
Oral: 50–60% (extensive first-pass metabolism)
Contraindicated in patients with GFR <30 m L/min. For GFR 30-60 m L/min: use with caution, reduce dose by 50%, monitor electrolytes. No adjustment for GFR >60 m L/min.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment necessary. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use due to risk of hepatic encephalopathy.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not recommended for pediatric use due to lack of safety and efficacy data.
Not recommended for pediatric use; safety in children under 12 years not established.
Initiate therapy at the lower end of the dosing range (1 capsule daily) due to increased sensitivity to orthostatic hypotension and electrolyte disturbances. Titrate slowly.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None.
None
First-dose syncope (orthostatic hypotension) can occur, especially with initial use or dose escalation,Sodium and water depletion may occur with thiazide, leading to hypokalemia, hyponatremia, and hypomagnesemia,May exacerbate renal impairment; monitor renal function,May increase serum uric acid and precipitate gout,May cause hypersensitivity reactions, including anaphylaxis and angioedema
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Anuria,Hypersensitivity to prazosin, polythiazide, or sulfonamide-derived drugs (thiazides),Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid high-potassium foods (e.g., bananas, oranges) if potassium-sparing diuretics or supplements are used; hydrochlorothiazide can cause hypokalemia so potassium-rich foods may be recommended. Grapefruit juice may increase prazosin levels; avoid.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
Prazosin-polythiazide combination. First trimester: Risk category C; limited human data. Second and third trimesters: potential fetal/neonatal effects include hypotension, electrolyte imbalance, and decreased placental perfusion. Avoid use unless clearly needed.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Prazosin: low levels in breast milk; M/P ratio 0.75-1.0. Polythiazide: may suppress lactation; M/P ratio unknown. Use caution, monitor infant for diuretic effects or hypotension.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Increased plasma volume and renal clearance may reduce drug levels; consider monitoring therapeutic effect and adjust dose accordingly. No fixed dosing guidelines; cautious titration recommended.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
MINIZIDE (prazosin/hydrochlorothiazide) is a fixed-dose combination for hypertension. Prazosin causes first-dose syncope; start with 1 mg at bedtime. Hydrochlorothiazide may cause hypokalemia; monitor potassium. Use cautiously in patients with history of angioedema from ACE inhibitors as prazosin may also cause angioedema.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take first dose at bedtime to avoid fainting.,Rise slowly from sitting or lying to prevent dizziness.,Avoid alcohol as it may worsen side effects.,Report episodes of fainting or rapid heartbeat.,Do not stop abruptly; may cause rebound hypertension.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MINIZIDE vs ALDORIL 15, answered by our medical review team.
MINIZIDE is a Antihypertensive Combination that works by Prazosin is a selective alpha-1 adrenergic antagonist that inhibits vascular smooth muscle contraction, reducing peripheral vascular resistance and blood pressure. Polythiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing sodium and water excretion, and reducing intravascular volume.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MINIZIDE and ALDORIL 15 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MINIZIDE is: 1-2 capsules orally twice daily; each capsule contains prazosin 0.5 mg and polythiazide 0.5 mg. Titrate based on blood pressure response.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MINIZIDE and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MINIZIDE is classified as Category C. Prazosin-polythiazide combination. First trimester: Risk category C; limited human data. Second and third trimesters: potential fetal/neonatal effects include hypotension, electrol. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.